In contrast to PIK3CA, where most activating point mutations occur [41] little is known about PIK3CB. Recent preclinical studies have shown that different PI3K isoforms play divergent roles in cellular signaling and cancer, and that is why isoform-selective inhibitors are now emerging as intensively explored agents in clinical trials [41, 42]. Here, PIK3CA is linked to cancer.